What is BioXcel Therapeutics?
BioXcel Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering transformative medicines within the neuroscience sector through the application of artificial intelligence. The company's wholly owned subsidiary, OnkosXcel Therapeutics, is actively engaged in developing novel treatments for immuno-oncology. This dual focus positions BioXcel at the intersection of cutting-edge AI technology and critical therapeutic areas, aiming to accelerate the discovery and development of innovative therapies.
How much funding has BioXcel Therapeutics raised?
BioXcel Therapeutics has raised a total of $260M across 1 funding round:
Other Financing Round
$260M
Other Financing Round (2022): $260M with participation from Oaktree and Qatar Investment Authority
Key Investors in BioXcel Therapeutics
Oaktree
Oaktree Capital Management is a leading global investment management firm specializing in alternative investments, known for its opportunistic and value-oriented approach across credit, equity, and real estate markets. They partner with clients worldwide to identify investment opportunities that balance potential returns with disciplined risk management.
Qatar Investment Authority
Founded in 2005, Qatar Investment Authority is a sovereign wealth fund based in Doha, Qatar, specializing in foreign and domestic investment with a focus on listed securities, property, alternative assets, and private equity.
What's next for BioXcel Therapeutics?
The significant enterprise-level capital infusion suggests BioXcel Therapeutics is poised for accelerated scaling and further clinical development. This strategic backing will likely fuel advancements in its AI-driven drug discovery pipeline, particularly in neuroscience and immuno-oncology. The company's trajectory indicates a strong emphasis on translating its technological advantages into tangible therapeutic solutions, potentially marking a new era in pharmaceutical innovation.
See full BioXcel Therapeutics company page
